RESEARCH TRIANGLE PARK, N.C., March 20, 2012 /PRNewswire/ -- AlphaVax, Inc. ("AVX") is pleased to report that it has been selected as a corporate nominee for the 2012 Vaccine Industry Excellence Award as the Best Early-Stage Vaccine Biotech Company. The award will be announced during the World Vaccine Congress meeting in Washington, DC in April.
AVX is pleased to be both included in the list of finalists as deemed by the panel of judges as well as being recognized as a leader in the field. The Company's proprietary replicon technology has been tested in several clinical trials involving approximately 400 patients. In concert with the Duke University Medical Center in Durham, NC, AVX is awaiting the initiation of a Phase I trial in HER2+ breast cancer.
Based in Research Triangle Park, NC, AVX has developed a new generation of vaccine products for diseases that represent significant market opportunities based on its novel, proprietary vector platform technology. AlphaVax is at the forefront of a completely new class of potent biopharmaceutical products aimed to participate in this market with its viral vector technology that has the clear potential to redefine the traditional concept of vaccines. The AlphaVax proprietary viral vector gene expression system has the potential for developing a range of effective vaccines in both cancer and infectious disease.
AlphaVax is focusing the commercial potential of its alphavaccine system in cancer immunotherapy. The development of immunotherapeutic treatments for cancer is a rapidly growing area in which AlphaVax will be taking a lead position in developing new treatment modalities utilizing its proprietary technology.
|SOURCE AlphaVax, Inc.|
Copyright©2010 PR Newswire.
All rights reserved